17:54 , Jul 26, 2017 |  BC Innovations  |  Emerging Company Profile

Breaching the gates

Junction Therapeutics Ltd. ’s siRNA-based technology creates transient openings in the blood-brain barrier by targeting tight junction proteins, allowing molecules to move in and out of the brain by diffusion. The approach enhances entry of...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Company News

biOasis, Vaccinex deal

biOasis granted Vaccinex commercialization rights to use biOasis’ Transcend delivery technology with Vaccinex’s anti- semaphorin 4D (SEMA4D) antibodies. biOasis is eligible for up to $20 million in upfront and milestone payments, plus single-digit royalties. Vaccinex...
07:00 , May 2, 2016 |  BC Week In Review  |  Company News

biOasis, Astellas deal

biOasis and Astellas’ Astellas Research Institute of America LLC unit partnered to develop biOasis’ Transcend technology. The technology platform facilitates delivery of therapeutics across the blood-brain barrier to brain tissue. The companies declined to disclose...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

Brigham and Women’s Hospital, biOasis deal

biOasis and the hospital partnered to advance compounds to treat brain cancers, including glioblastoma tumors. The initial focus will be on advancing biOasis’ Transcend peptide carrier, MTfp, to the clinic. The partners will work to...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Company News

biOasis, National Research Council Canada, Universite de Sherbrooke deal

biOasis partnered with the National Research Council of Canada and the Universite de Sherbrooke to identify blood-brain barrier (BBB) carrier molecules for use with neurotherapeutics. The partners have been awarded C$2.6 million ($2 million) in...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Financial News

biOasis proposes private placement of units

biOasis Technologies Inc. (TSX-V:BTI; OTCQX:BIOAF), Vancouver, B.C.   Business: Neurology, Diagnostic   Date announced: 2014-08-08   Type: Private placement of units   To be raised: Up to C$1.5 million ($1.4 million)   Units: 1.6 million...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Company News

biOasis management update

Judi Dalling as CFO and corporate secretary; she succeeds David Clark, who resigned biOasis Technologies Inc. (TSX-V:BTI; OTCQX:BIOAF), Vancouver, B.C.   Business: Neurology, Diagnostic  ...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

biOasis, AstraZeneca deal

biOasis partnered with AstraZeneca's MedImmune LLC biologics unit to evaluate MedImmune's preclinical compounds with next-generation versions of biOasis' Transcend brain delivery technology. Transcend is a soluble p97 (melanotransferrin) carrier protein that transports therapeutics across the...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Clinical News

biOasis preclinical data

In mice inoculated with a HER2-overespressing human breast cancer cell line that migrated to the brain and established brain tumors, twice-weekly subcutaneous BT2111 significantly reduced the mean number of HER2+ breast cancer tumors in the...
08:00 , Dec 24, 2012 |  BioCentury  |  Product Development

Shire homes in

Proof-of-concept data in cancer for Arrowhead Research Corp. 's peptide-based tissue targeting platform were good enough to get Shire plc on board to use the technology for rare diseases. Last week, the companies partnered to...